Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Infectious Diseases

• Publication date

  2015-01-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/infdis/jiv005PMID 25583164PMCID PMC5007583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

  2015cited by this paper
• Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

  2014cited by this paper
• Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

  2014influential reference
• Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.

  2014influential reference
• Patient‐reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir‐containing regimens

  2014cited by this paper
• P1324 LEDIPASVIR (LDV) AND SOFOSBUVIR (SOF) COMBINATION IMPROVES PATIENT-REPORTED OUTCOMES (PRO) DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) PATIENTS: RESULTS FROM THE ION-1 CLINICAL TRIAL

  2014cited by this paper
• Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000

  2014cited by this paper
• The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions

  2014cited by this paper
• Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.

  2014cited by this paper
• The impact of hepatitis C burden: an evidence‐based approach

  2014cited by this paper
• Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

  2014cited by this paper
• Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

  2014influential reference
• Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale.

  2013cited by this paper
• Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

  2013cited by this paper
• Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain.

  2013cited by this paper
• Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study

  2013cited by this paper
• Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic

  2009cited by this paper
• Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis

  2008cited by this paper
• Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

  2008cited by this paper
• Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

  2008cited by this paper
• Current status of HIV infection: a review for non‐HIV‐treating physicians

  2007cited by this paper
• Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection

  2007cited by this paper
• Epidemiology of viral hepatitis and HIV co-infection.

  2006cited by this paper
• Rates and predictors of hepatitis C virus treatment in HCV–HIV‐coinfected subjects

  2006cited by this paper
• Comparison of WHOQOL-BREF and SF-36 in patients with HIV infection

  2005cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

  2004cited by this paper
• Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection.

  2004cited by this paper
• Reliability and validity of the SF-36 in HIV-infected homeless and marginally housed individuals

  2003cited by this paper
• Hepatitis C virus and human immunodeficiency virus coinfection in Spain.

  2003cited by this paper
• Hepatitis C in the HIV-Infected Person

  2003cited by this paper
• Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

  2002cited by this paper
• The RAND-36 measure of health-related quality of life

  2001influential reference
• Health-Related Quality of Life in Individuals Infected with HIV in the Era of HAART

  2001cited by this paper
• Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study.

  2000cited by this paper
• Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease

  1999cited by this paper
• [Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus].

  1997cited by this paper
• Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study.

  1994cited by this paper
• Increasing Hepatitis C Virus RNA Levels in Hemophiliacs: Relationship to Human Immunodeficiency Virus Infection and Liver Disease

  1994cited by this paper
• The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument

  1993cited by this paper

• The Era of DAAs: Assessing the Patients’ Characteristics, Clinical Impact, and Emergence of Comorbidities in HIV/HCV-Coinfected versus HIV-Infected Individuals

  2024cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• When and in Whom to Initiate HCV Therapy

  2023cites this paper
• Assessment of Knowledge Regarding Hepatitis C Transmission, Treatment, and Vaccination among Health Care Providers

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• When and in Whom to Initiate HCV Therapy

  2022cites this paper
• The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals

  2021cites this paper
• Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection

  2021cites this paper
• Patient-reported outcomes for HIV: the future of long-acting injectables and antiretroviral therapy evaluations

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2021cites this paper
• Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response.

  2021cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• When and in Whom to Initiate HCV Therapy

  2020cites this paper
• Manifestations extrahépatiques secondaires à l’infection chronique par le virus de l’hépatite C

  2019cites this paper
• Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection

  2019cites this paper
• A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases.

  2019cites this paper
• Patient‐reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication

  2019cites this paper
• Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

  2019cites this paper
• Quality of life in patients with hepatitis C. Importance of treatment.

  2019cites this paper
• Pro fi le of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper
• When and in Whom to Initiate HCV Therapy

  2019cites this paper